{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'may jeopardize the patient and may require medical or surgical intervention to prevent 1 of the', 'outcomes listed in this definition. Examples of such events include allergic bronchospasm', 'requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions', 'that do not result in in-patient hospitalization, or the development of drug dependency or drug', 'abuse.', '12.2.1.', 'Events that Do Not Meet the Definition of a Serious Adverse Event', 'Elective hospitalizations to administer, or to simplify study treatment or study procedures (ie, an', 'overnight stay to facilitate 24-hour urine collection) or other medical procedures are not', 'considered SAEs. A \"serious\\' hospitalization is defined as any inpatient hospital admission that', 'includes a minimum of an overnight stay in a health care facility. An emergency room visit is not', 'considered a hospitalization unless it results in an official admission as an inpatient to the', 'hospital (eg, undesirable effects of any administered treatment) and must be documented as an', 'SAE.', 'Progression of the malignancy/disease (including fatal outcomes) should NOT be reported as an', 'SAE during the study or within the safety reporting period (see Section 12.2.3). Sudden or', 'unexplained death should be reported as an SAE. If there is any uncertainty about a finding being', 'due solely to progression of malignancy/disease, the finding should be reported as an AE or', 'SAE, as appropriate.', '12.2.2.', 'Recording of Serious Adverse Events', 'It is the responsibility of the Investigator to record and document all SAEs occurring from the', 'time when the ICF is signed until at least 30 days after the patient has stopped study treatment.', \"All SAEs must be reported on the designated Sponsor's SAE Report Form in addition to being\", \"recorded in the eCRF. The original SAE report form must be retained in the Investigator's site\", 'file.', 'All applicable sections of the SAE Report Form must be completed in order to provide a', 'clinically thorough report. The Investigator must assess and record the relationship of each SAE', 'to study treatment and complete the form in English.', 'See ICH E2A (Clinical Safety Data Management: Definitions and Standards for Expedited', 'Reporting, Attachment 1) for key data elements that are required for expedited reporting.', '12.2.3.', 'Reporting of Serious Adverse Events', 'Every SAE, regardless of the causal relationship to the study treatment, occurring after the', 'patient has signed informed consent, until at least 30 days after the patient has stopped study', 'treatment, must be reported to the Karyopharm Pharmacovigilance Department within 24 hours', 'of learning of its occurrence. The investigational site personnel must use the SAE Report Form', 'provided by Karyopharm for reporting any SAE to the Karyopharm Pharmacovigilance', 'Department.', 'Confidential', 'Page 89', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Upon completion, the SAE Report Form must be immediately emailed or faxed to:', 'Pharmacovigilance Department', 'Karyopharm Therapeutics Inc.', 'Email: pharmacovigilance@karyopharm.com', 'Fax:', '+1-617-334-7617 (USA)', '+49-89-9218-5650 (Germany)', 'Any SAE observed after the 30-day follow-up period should only be reported to Karyopharm if', 'the Investigator suspects that the SAE has a causal relationship to the study treatment. Recurrent', 'episodes, complications, or progression of the initial SAE must be reported, as follow-up to the', 'original episode, within 24 hours of the Investigator receiving the follow-up information.', 'An SAE should be followed until its resolution or until it is judged to be permanent. An', 'assessment should be made at each study visit (or more frequently, if necessary) of any changes', 'in severity of the event, the suspected relationship to the study treatment, the interventions', 'required to treat the event, and the outcome of the event.', '12.2.4.', 'Suspected Unexpected Serious Adverse Reactions', 'Suspected unexpected serious adverse reactions (SUSARs) are SAEs that are unexpected and', 'judged by the Investigator or Karyopharm to be related to the study treatment administered. All', 'SUSARs will be collected and reported to the competent authorities and relevant ethics', 'committees in accordance with the FDA\\'s \"Safety Reporting Requirements for Investigational', 'New Drugs and Bioanalytical/Bioequivalence Studies\" or as per national regulatory requirements', 'in participating countries.', 'In addition, Karyopharm will communicate all cases of cerebellar toxicity, Grade 3 or higher, to', 'regulatory authorities, central ethics committees (eg, IRBs), and Investigators, in the format of an', 'expedited Safety Report, within 7 days of awareness of the event.', 'If required by local regulations, the Investigator is responsible for notifying his/her IRB or local', 'ethics committee of all SAEs.', '12.3.', 'Procedures for Handling Special Situations', '12.3.1.', 'Pregnancy and Breastfeeding', 'Note: Pregnancy per se is not considered to be an AE; however, it is discussed here because of', 'the importance of reporting pregnancies that occur during studies and because a medical', 'occurrence observed in the mother or fetus/newborn would be classified as an AE.', 'Female patients of childbearing potential and fertile male patients will be informed as to the', 'potential risk of conception while participating in this study and will be advised that they must', 'use highly effective contraception listed in Section 10.8.1 (ie, results in a low failure rate when', 'used consistently and correctly) during the dosing period and for a period of at least 3 months', 'after the end of treatment.', 'Confidential', 'Page 90', 'Version 4.0']\n\n###\n\n", "completion": "END"}